{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T02:52:50Z","timestamp":1722653570062},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T00:00:00Z","timestamp":1487721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>Intravenous immunoglobulins (<jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content>s) are a common therapy in patients with neuroinflammatory disorders, especially chronic inflammatory demyelinating polyradiculoneuropathy or Guillain\u2212Barr\u00e9 syndrome. Hematological toxicities upon <jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content> infusion are a known side effect and still an important subject of investigation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Laboratory results and data for clinical efficacy and tolerability of 62 patients with neuroinflammatory disorders treated with <jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content> (0.4 g\/kg bodyweight per day over 5 days) at the Department of Neurology, University of Duisburg\u2010Essen, Germany, were retrospectively analyzed. Blood samples were taken before and 1 day after <jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content> administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In pre\u2010treated and first\u2010time treated patients, there was a significant decrease in white blood cell count (<jats:styled-content style=\"fixed-case\">WBC<\/jats:styled-content>) (8.10 \u00b1 2.85\/nl to 5.61 \u00b1 2.50\/nl, <jats:italic>P<\/jats:italic> &lt; 0.001, <jats:italic>n<\/jats:italic> = 57) and platelets (255 \u00b1 72\/nl to 215 \u00b1 66\/nl, <jats:italic>P<\/jats:italic> &lt; 0.001, <jats:italic>n<\/jats:italic> = 57). Mild hemolysis of red blood cells was found in patients who received <jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content> for the first time (red blood cell count 4.61 \u00b1 0.67\/pl to 4.28 \u00b1 0.52\/pl, hemoglobin 13.7 \u00b1 1.7 g\/l to 13.0 \u00b1 1.7 g\/l, <jats:italic>P<\/jats:italic> &lt; 0.001, <jats:italic>n<\/jats:italic> = 40). Hemolysis was associated with less tolerability of <jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content> treatment and clinical efficacy was accompanied with a higher decline of <jats:styled-content style=\"fixed-case\">WBC<\/jats:styled-content> (not significant).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Next to mild hemolysis, a significant decrease in <jats:styled-content style=\"fixed-case\">WBC<\/jats:styled-content> and platelets can be detected early after high dose <jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content>s in patients with neuroinflammatory disorders. Changes in blood counts may be possible markers for clinical efficacy and tolerability. Patients with low blood counts in advance should be particularly closely monitored whilst on <jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content> treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.13264","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T05:52:42Z","timestamp":1487742762000},"page":"638-644","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Early platelet and leukocyte decline in patients with neuroinflammatory disorders after intravenous immunoglobulins"],"prefix":"10.1111","volume":"24","author":[{"given":"A.","family":"Totzeck","sequence":"first","affiliation":[{"name":"Department of Neurology University Hospital Essen Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Stettner","sequence":"additional","affiliation":[{"name":"Department of Neurology University Hospital Essen Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Hagenacker","sequence":"additional","affiliation":[{"name":"Department of Neurology University Hospital Essen Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,2,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02246.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90112-4"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12287"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1142::AID-MUS8>3.0.CO;2-8"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2011.11.004"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2011.07.024"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.1986.tb00071.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.01000.x"},{"key":"e_1_2_6_10_1","first-page":"28","article-title":"Treatment of acute immune thrombocytopenic purpura","volume":"35","author":"Tarantino MD","year":"1998","journal-title":"Semin Hematol"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.3.674"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13113"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201233260413"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2008.00741.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200311000-00009"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021568"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90806-E"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2013.05.009"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2014.06.007"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-003-1085-1"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13727"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1993.tb00150.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-12-1067"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306227"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200310000-00011"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13097"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fene.13264","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.13264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:45:30Z","timestamp":1695494730000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.13264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,22]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1111\/ene.13264"],"URL":"https:\/\/doi.org\/10.1111\/ene.13264","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,22]]},"assertion":[{"value":"2016-09-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}